Skip to main content
. 2023 Mar 22;11:1155481. doi: 10.3389/fped.2023.1155481

Table 2.

Three assessments of blood biochemistry, electrolytes, and coagulation function in ALL and AML patients.

Variable First Second Third F (P-value)
ALT (IU/L)
 ALL 74.5 ± 37.4 63.5 ± 26.7 48.8 ± 22.1 6.14 (0.0031)
 AML 79.5 ± 40.2 68.6 ± 28.8 46.7 ± 20.6 4.38 (0.0188)
AST (IU/L)
 ALL 79.4 ± 65.9 53.8 ± 35.3 36.4 ± 17.6 7.61 (0.0009)
 AML 75.2 ± 62.1 55.0 ± 37.9 35.3 ± 14.1 3.26 (0.0482)
TBil (μmol/L)
 ALL 35.0 ± 15.9 29.2 ± 7.7 21.3 ± 6.0 13.22 (0.0000)
 AML 37.8 ± 17.2 28.4 ± 8.7 22.6 ± 6.3 6.44 (0.0036)
BUN (mmol/L)
 ALL 8.54 ± 2.43 7.12 ± 2.19 5.33 ± 1.32 19.96 (0.0000)
 AML 8.40 ± 2.24 6.86 ± 2.06 5.51 ± 1.49 8.20 (0.0010)
Creatinine (μmol/L)
 ALL 128.9 ± 44.2 107.6 ± 32.0 78.3 ± 18.4 18.68 (0.0000)
 AML 124.3 ± 45.8 100.7 ± 31.8 82.7 ± 19.7 5.60 (0.0070)
Troponin-I (ng/L)
 ALL 2.37 ± 1.64 1.85 ± 1.06 1.62 ± 0.89 3.08 (0.0508)
 AML 2.28 ± 1.56 1.92 ± 1.13 1.61 ± 0.92 1.11 (0.3389)
CK-MB (μg/L)
 ALL 3.42 ± 2.88 2.23 ± 1.62 1.78 ± 0.85 5.92 (0.0038)
 AML 3.57 ± 2.60 2.58 ± 1.70 1.75 ± 0.82 3.62 (0.0355)
Na+ (mmol/L)
 ALL 139.7 ± 3.1 140.1 ± 2.5 139.9 ± 2.7 0.17 (0.8474)
 AML 139.3 ± 3.3 139.8 ± 2.8 140.0 ± 2.6 0.23 (0.7959)
K+ (mmol/L)
 ALL 5.44 ± 0.71 4.76 ± 0.57 4.42 ± 0.60 21.78 (0.0000)
 AML 5.38 ± 0.66 4.68 ± 0.59 4.47 ± 0.63 8.65 (0.0007)
Ca2+ (mmol/L)
 ALL 2.01 ± 0.15 1.96 ± 0.11 1.95 ± 0.12 2.02 (0.1378)
 AML 1.99 ± 0.14 1.92 ± 0.12 1.93 ± 0.10 1.47 (0.2424)
PT (s)
 ALL 13.8 ± 2.5 13.3 ± 1.7 12.5 ± 0.9 4.15 (0.0188)
 AML 14.6 ± 2.3 13.6 ± 1.6 12.7 ± 1.1 4.49 (0.0171)
APTT (s)
 ALL 40.4 ± 8.3 36.1 ± 5.1 33.3 ± 3.1 11.75 (0.0000)
 AML 42.8 ± 9.2 37.3 ± 6.4 34.6 ± 3.5 5.70 (0.0065)

ALL, acute lymphocytic leukemia; AML, acute myeloblastic leukemia; ALT, alanine aminotransferase; AST, aspartate aminotransferase; TBil, total bilirubin; BUN, blood urea nitrogen; CK-MB, creatine kinase; PT, prothrombin time; APTT, activated partial thromboplastin time; ANOVA, analysis of variance.

The results were compared using ANOVA.